Paper36498669
Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis.
Gu S and 7 others. J Clin Med, 2022. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis. Papers, record 36498669. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36498669
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 72104102 | National Natural Science Foundation of China | PubMed | ||
| 20JD001 | Jiangsu Planning Office of Philosophy and Social Science | PubMed |
Source PubMed
References145
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18355325 | Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. | Diabetes Obes Metab | 2008 | https://conductscience.org/library/papers/18355325 | PubMed |
| 2 | 24622369 | Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet Diabetes Endocrinol | 2013 | https://conductscience.org/library/papers/24622369 | PubMed |
| 3 | 15549021 | Prevalence of overweight and obesity among adults with diagnosed diabetes--United States, 1988-1994 and 1999-2002. | MMWR Morb Mortal Wkly Rep | 2004 | https://conductscience.org/library/papers/15549021 | PubMed |
| 4 | 17223217 | Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. | Diabetes Res Clin Pract | 2007 | https://conductscience.org/library/papers/17223217 | PubMed |
| 5 | 18355324 | Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. | Diabetes Obes Metab | 2008 | https://conductscience.org/library/papers/18355324 | PubMed |
| 6 | 27171508 | Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong. | J Diabetes | 2017 | https://conductscience.org/library/papers/27171508 | PubMed |
| 7 | 23279307 | Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. | Diabetes Obes Metab | 2013 | https://conductscience.org/library/papers/23279307 | PubMed |
| 8 | 20332588 | Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. | Endocr J | 2010 | https://conductscience.org/library/papers/20332588 | PubMed |
| 9 | 16189256 | Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin. | J Clin Endocrinol Metab | 2005 | https://conductscience.org/library/papers/16189256 | PubMed |
| 10 | 21146883 | Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. | Diabetes Res Clin Pract | 2011 | https://conductscience.org/library/papers/21146883 | PubMed |
| 11 | 24400655 | Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study. | Diabetes Obes Metab | 2014 | https://conductscience.org/library/papers/24400655 | PubMed |
| 12 | 27088241 | Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. | Ann Intern Med | 2016 | https://conductscience.org/library/papers/27088241 | PubMed |
| 13 | 18201212 | Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. | Diabet Med | 2008 | https://conductscience.org/library/papers/18201212 | PubMed |
| 14 | 16823726 | Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. | Horm Metab Res | 2006 | https://conductscience.org/library/papers/16823726 | PubMed |
| 15 | 25238025 | Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes. | Diabetes Obes Metab | 2015 | https://conductscience.org/library/papers/25238025 | PubMed |
| 16 | 20334663 | Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. | Cardiovasc Diabetol | 2010 | https://conductscience.org/library/papers/20334663 | PubMed |
| 17 | 15154941 | An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. | Diabet Med | 2004 | https://conductscience.org/library/papers/15154941 | PubMed |
| 18 | 12682825 | Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients. | Acta Diabetol | 2003 | https://conductscience.org/library/papers/12682825 | PubMed |
| 19 | 19622552 | The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. | BMJ | 2009 | https://conductscience.org/library/papers/19622552 | PubMed |
| 20 | 18495285 | Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. | Diabetes Res Clin Pract | 2008 | https://conductscience.org/library/papers/18495285 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41981598 | Prediction model for metformin intolerance in Chinese elderly patients with type 2 diabetes: derivation and external validation in a cross‑sectional study. | BMC Endocr Disord | 2026 | https://conductscience.org/library/papers/41981598 | PubMed |
| 38700730 | [Preoperative evaluation of adult patients before elective, non-cardiothoracic surgery : A joint recommendation of the German Society for Anesthesiology and Intensive Care Medicine, the German Society for Surgery and the German Society for Internal Medicine]. | Anaesthesiologie | 2024 | https://conductscience.org/library/papers/38700730 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| GLP1R | 2740 | PubTator's text mining | https://conductscience.org/library/genes/2740 | NCBI Gene |
| INS | 3630 | PubTator's text mining | https://conductscience.org/library/genes/3630 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36498669
GET https://conductscience.org/api/papers/v1/36498669/references?page=2